These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 29222267

  • 1. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD, Motta I.
    Hematology Am Soc Hematol Educ Program; 2017 Dec 08; 2017(1):278-283. PubMed ID: 29222267
    [Abstract] [Full Text] [Related]

  • 2. 2021 update on clinical trials in β-thalassemia.
    Musallam KM, Bou-Fakhredin R, Cappellini MD, Taher AT.
    Am J Hematol; 2021 Nov 01; 96(11):1518-1531. PubMed ID: 34347889
    [Abstract] [Full Text] [Related]

  • 3. [Overview of new approaches to β-thalassemia treatment].
    Guo XF, Han L, Zhang XC, Zhang HH, Liu J.
    Sheng Li Xue Bao; 2024 Jun 25; 76(3):496-506. PubMed ID: 38939943
    [Abstract] [Full Text] [Related]

  • 4. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN, Taher AT.
    Ann N Y Acad Sci; 2016 Mar 25; 1368(1):82-94. PubMed ID: 27186941
    [Abstract] [Full Text] [Related]

  • 5. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
    Di Modica SM, Tanzi E, Olivari V, Lidonnici MR, Pettinato M, Pagani A, Tiboni F, Furiosi V, Silvestri L, Ferrari G, Rivella S, Nai A.
    Am J Hematol; 2022 Oct 25; 97(10):1324-1336. PubMed ID: 36071579
    [Abstract] [Full Text] [Related]

  • 6. [Current management of thalassemia intermedia].
    Thuret I.
    Transfus Clin Biol; 2014 Nov 25; 21(4-5):143-9. PubMed ID: 25282488
    [Abstract] [Full Text] [Related]

  • 7. Iron overload in thalassemia: different organs at different rates.
    Taher AT, Saliba AN.
    Hematology Am Soc Hematol Educ Program; 2017 Dec 08; 2017(1):265-271. PubMed ID: 29222265
    [Abstract] [Full Text] [Related]

  • 8. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
    Motta I, Bou-Fakhredin R, Taher AT, Cappellini MD.
    Drugs; 2020 Jul 08; 80(11):1053-1063. PubMed ID: 32557398
    [Abstract] [Full Text] [Related]

  • 9. Beta Thalassemia: Monitoring and New Treatment Approaches.
    Khandros E, Kwiatkowski JL.
    Hematol Oncol Clin North Am; 2019 Jun 08; 33(3):339-353. PubMed ID: 31030806
    [Abstract] [Full Text] [Related]

  • 10. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
    Shash H.
    Medicina (Kaunas); 2022 Oct 21; 58(10):. PubMed ID: 36295656
    [Abstract] [Full Text] [Related]

  • 11. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.
    Jones E, Pasricha SR, Allen A, Evans P, Fisher CA, Wray K, Premawardhena A, Bandara D, Perera A, Webster C, Sturges P, Olivieri NF, St Pierre T, Armitage AE, Porter JB, Weatherall DJ, Drakesmith H.
    Blood; 2015 Jan 29; 125(5):873-80. PubMed ID: 25519750
    [Abstract] [Full Text] [Related]

  • 12. Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia.
    Ricchi P, Meloni A, Costantini S, Spasiano A, Di Matola T, Pepe A, Cinque P, Filosa A.
    Ann Hematol; 2017 Sep 29; 96(9):1541-1546. PubMed ID: 28707012
    [Abstract] [Full Text] [Related]

  • 13. Pathophysiology and Clinical Manifestations of the β-Thalassemias.
    Nienhuis AW, Nathan DG.
    Cold Spring Harb Perspect Med; 2012 Dec 01; 2(12):a011726. PubMed ID: 23209183
    [Abstract] [Full Text] [Related]

  • 14. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
    Asadov C, Alimirzoeva Z, Mammadova T, Aliyeva G, Gafarova S, Mammadov J.
    Int J Hematol; 2018 Jul 01; 108(1):5-21. PubMed ID: 29380178
    [Abstract] [Full Text] [Related]

  • 15. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
    Kalleda N, Flace A, Altermatt P, Ingoglia G, Doucerain C, Nyffenegger N, Dürrenberger F, Manolova V.
    Haematologica; 2023 Oct 01; 108(10):2703-2714. PubMed ID: 37165842
    [Abstract] [Full Text] [Related]

  • 16. New strategies in the treatment of the thalassemias.
    Schrier SL, Angelucci E.
    Annu Rev Med; 2005 Oct 01; 56():157-71. PubMed ID: 15660507
    [Abstract] [Full Text] [Related]

  • 17. How I treat non-transfusion-dependent β-thalassemia.
    Saliba AN, Musallam KM, Taher AT.
    Blood; 2023 Sep 14; 142(11):949-960. PubMed ID: 37478396
    [Abstract] [Full Text] [Related]

  • 18. An update on thalassemia intermedia.
    Maakaron JE, Cappellini MD, Taher AT.
    J Med Liban; 2013 Sep 14; 61(3):175-82. PubMed ID: 24422369
    [Abstract] [Full Text] [Related]

  • 19. Alpha- and Beta-thalassemia: Rapid Evidence Review.
    Baird DC, Batten SH, Sparks SK.
    Am Fam Physician; 2022 Mar 01; 105(3):272-280. PubMed ID: 35289581
    [Abstract] [Full Text] [Related]

  • 20. Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
    Pinto VM, Forni GL.
    Int J Mol Sci; 2020 Nov 20; 21(22):. PubMed ID: 33233561
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.